News-MedicalTirzepatide cuts diabetes risk by 90% in obese patients, study showsTirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other…news-medical.netTirzepatide cut progression from prediabetes to diabetes by over 90%
Gokhan notes that tirzepatide (a GLP-1/GIP drug) cut the chance of progressing from prediabetes to diabetes by over 90%, linking a ScienceAlert report of a 94% reduction in adults with obesity or overweight and prediabetes.


